Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease

Quazim A. Alayo, MD,‡,1,2 Marc Fenster, MD,‡ Osama Altyayr, MD,‡ Kerri L. Glassner, DO,‡ Ernesto Llano, MD,1 Kindra Clark-Snustad, DNP,∗ Anish Patel, DO,†† Lukasz Kwapisz, MD,‡‡

Andres J. Yarur, MD,¶¶ Benjamin L. Cohen, MD,¶¶ Matthew A. Ciorba, MD,¶ Deborah Thomas, MLS,§§ Scott D. Lee, MD,†† Edward V. Loftus Jr., MD,∗∗ David I. Fudman, MD,¶ Bincy P. Abraham, MD,¶ Jean-Frederic Colombel, MD,†††,¶¶ and Parakkal Deepak, MD,¶¶

1Department of Internal Medicine, St. Luke’s Hospital, St. Louis, Missouri, USA
2Division of Gastroenterology and Hepatology, Washington University in Saint Louis School of Medicine, St. Louis, Missouri, USA
3Division of Gastroenterology, Albert Einstein College of Medicine, Montefiore Medical Centre, Bronx, New York, USA
4Division of Gastroenterology, Washington University in Saint Louis School of Medicine, St. Louis, Missouri, USA
5Division of Gastroenterology and Hepatology, Houston Methodist Hospital, Houston, Texas, USA
6Division of Digestive and Liver Diseases, University of Texas Southwestern, Dallas, Texas, USA
7Division of Gastroenterology, University of Washington Medical Centre, Seattle, Washington, USA
8Division of Gastroenterology, Brooke Army Medical Centre, Fort Sam Houston, Texas, USA
9Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA
10Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
11Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA
12Division of Gastroenterology, Brooke Army Medical Centre, Fort Sam Houston, Texas, USA
13Division of Gastroenterology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
14Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Address correspondence to: Parakkal Deepak, MBBS, MS, John T. Miliken Department of Medicine, Division of Gastroenterology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA (deepak.parakkal@wustl.edu).

Background: Combining biologics and small molecules could potentially overcome the plateau of drug efficacy in inflammatory bowel disease (IBD). We conducted a systematic review and meta-analysis to assess the safety and effectiveness of dual biologic therapy (DBT), or small molecule combined with a biologic therapy (SBT) in IBD patients.

Methods: We searched MEDLINE, EMBASE, Scopus, Web of Science, Cochrane Database of Systematic Reviews, and Clinical trials.gov until November 3, 2020, including studies with 2 or more IBD patients on DBT or SBT. Main outcome was safety assessed as pooled rates of adverse events (AEs) and serious AEs (SAEs) for each combination. Effectiveness was reported as pooled rates of clinical, endoscopic, and/or radiographic response and remission. The certainty of evidence was rated according to the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) framework.

Results: Of the 3688 publications identified, 13 studies (1 clinical trial, 12 observational studies) involving 266 patients on 7 different combinations were included. Median number of prior biologics ranged from 0 to 4, and median duration of follow-up was 16–68 weeks. Most common DBT and SBT were vedolizumab (VDZ) with anti-tumor necrosis factor (aTNF, n = 56) or tofacitinib (Tofa, n = 57), respectively. Pooled rates of SAE for these were 9.6% (95% confidence interval [CI], 1.5–21.4) for VDZ-aTNF and 1.0% (95% CI, 0.0–7.6) for Tofa-VDZ. The overall certainty of evidence was very low due to the observational nature of the studies, and very serious imprecision and inconsistency.

Conclusions: DBT or SBT appears to be generally safe and may be effective in IBD patients, but the evidence is very uncertain.

Lay Summary

Our study suggests that a combination of 2 biologics or a biologic with a small molecule drug appears safe, with no new adverse event signal. These combinations may be potentially effective as a therapeutic option in treatment refractory inflammatory bowel disease patients, but the evidence is very uncertain.

Key Words: inflammatory bowel diseases, biologics, ulcerative colitis, Crohn’s disease, meta-analysis

Introduction

The morbidity associated with persistent inflammation in inflammatory bowel disease (IBD) has spurred a shift in the goals of therapy from the control of symptoms to achieving corticosteroid-free sustained complete remission including endoscopic remission.1–4 Since the approval of the first tumor
necrosis factor antagonist (anti-TNF) for IBD treatment about 2 decades ago, several other biologics and small molecule drugs (SMDs) including vedolizumab (VDZ), ustekinumab (UST), and tofacitinib (Tofa) have been approved for patients with moderate-to-severe IBD. Despite these new advances, many patients do not achieve sustained complete remission, with about 40% of patients having persistent symptoms and/or mucosal disease after 1 year of biologic therapy and a fifth requiring surgery within 2–5 years of therapy.6,7

The failure to achieve sustained complete remission with biologics or SMDs has led to an increasing interest in exploring the therapeutic potential of combining mechanistically different biologics, or biologics with a small molecule therapy in refractory IBD patients. Furthermore, IBD patients often have concomitant extraintestinal manifestations sometimes necessitating combining biologics and/or small molecules. However, there are concerns about the safety of this approach, especially because studies on combination therapies in the rheumatological literature have demonstrated concerning safety profiles.7 To date, the only randomized controlled trial (RCT) of combination therapy in IBD compared the combination of infliximab (anti-TNF) with the anti-integrin natalizumab (NAT) to infliximab monotherapy, and it reported no new safety signal.8 A prior systematic review and pooled analysis of 7 studies on dual therapy with biologics across a total of 18 patients also reported no new safety signal.8 Since this review, several other studies have been published reporting on the safety and effectiveness of dual biologic therapy (DBT) or a biologic plus a small molecule therapy (SBT) in IBD patients.9–11 A more recent systematic review and meta-analysis12 provided pooled safety and efficacy estimates across all patients on 9 different DBT and SBT that do not account for the significant heterogeneity in individual combination types. It also did not provide point estimates for safety and effectiveness for individual combinations necessary for shared decision making when considering combination therapy in an individual patient.

The aim of this study therefore was to provide a more comprehensive systematic review and meta-analysis to assess the safety and effectiveness of DBTs and SBTs in patients with IBD across the various individual combinations and to identify gaps for future study of this emerging concept in IBD therapy.

Methods
Search Strategy and Study Selection
We conducted a systematic review and meta-analysis by systematically searching MEDLINE, EMBASE, Scopus, Web of Science, Cochrane Database of Systematic Reviews, and Clinical trials.gov to identify relevant studies published from the date of each database’s inception up to November 3, 2020, using keywords shown in Supplementary Table S1. The searches were limited to the English language and to human studies. Reference lists of review articles that were published in the same period were also searched. When abstracts were identified, we periodically search for the final publication to be included in the systematic review. We also included studies that some of the authors of this review participated in and were awaiting journals decisions.

Literature search was done by an experienced medical librarian (D.T.). Two authors (Q.A.A. and M.F.) independently screened all article titles and abstracts for relevance, based on inclusion and exclusion criteria. Full texts were retrieved, assessed for eligibility and data extracted independently for each study, using a predefined protocol and recorded on a form using REDCap (Research Electronic Data Capture, version 7.3.5) hosted at Washington University School of Medicine in St. Louis.13,14 Any disagreement between investigators was resolved by consensus between them and in discussion with a third author (P.D.). The review was reported in accordance with the MOOSE15 and PRISMA16 guidelines. The systematic review was registered with PROSPERO, CRD42020183611.

Inclusion and Exclusion Criteria
Studies were included if they met the following criteria: randomized controlled trials (RCTs) or observational studies; involved 2 or more IBD patients, including IBD-U (IBD-unclassified) patients; patients were treated concurrently with a combination of any 2 of the following biologics (anti-TNFs [infliximab, adalimumab, certolizumab pegol, golimumab], NAT, UST, or VDZ or small molecule therapy [Tofa]); and reported effectiveness and/or safety for the combination. Single case reports and narrative reviews were excluded. Patients on drugs that are not FDA approved for IBD were excluded. In instances of missing or incomplete data, corresponding authors were contacted to obtain additional data.

Study Outcomes and Data Synthesis
The main outcome of interest was safety assessed as pooled rates of any adverse events (AEs) and serious AEs (SAEs) for each combination. SAEs were defined as AEs which were life-threatening or resulting in a hospitalization, disability, or discontinuation of therapy. Other outcomes included pooled rates of infectious SAEs and gastrointestinal infections. We also assessed effectiveness of combination therapy as pooled rates of clinical response and remission, and endoscopic/radiographic response and remission. Clinical response/remission or endoscopic/radiographic response/remission were taken as reported by the authors regardless of response definition or scoring system used. For sensitivity analysis, we also assessed effectiveness limited to DBT or SBT used primarily for luminal disease. Some of the included studies had patients who underwent multiple therapeutic trials (TTs) and reported effectiveness per trial. However, all included studies reported safety outcomes per patient regardless of number of TTs. We therefore reported safety outcomes per patient and effectiveness per TTs.

Quality Assessment and Statistical Analysis
We assessed the quality of each study using a methodological quality appraisal tool for case series studies by Moga et al.17 We did not use a quantitative score to summarize the risk of bias per study; rather, we based the global judgment on the domains listed above.18 Risk of bias of RCTs was assessed using the same tool since the review and meta-analysis will only calculate pooled proportion of a single arm of RCTs (intervention arm) without relative effect size (ES) calculation. Additionally, we also assessed risk of bias in RCTs using the Cochrane Collaboration’s tool for assessing risk of bias in randomized trials.19 The overall certainty in evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach.20
All statistical analyses were performed using R version 4.0.3\textsuperscript{21} and the package \textit{meta} 4.15-1,\textsuperscript{22} The proportions of patients who developed AEs or achieved response or remission were pooled using the Freeman–Tukey double arc sine transformation and the DerSimonian and Laird random-effects model.\textsuperscript{23,24} The random-effects model was selected due to the anticipated clinical heterogeneity.\textsuperscript{25} Where possible, the generalized linear mixed model (GLMM) was used for sensitivity analysis. Heterogeneity between studies was quantified using the I-squared ($I^2$) statistic, with values of <30\%, 30\%–60\%, 61\%–75\%, and >75\% being suggestive of low, moderate, substantial, and considerable heterogeneity, respectively.\textsuperscript{26} Publication bias was assessed using asymmetry tests when appropriate.\textsuperscript{27}

Ethical Considerations

This study is exempt from IRB approval because publicly available data that were part of IRB-approved study protocols was used in data synthesis.

Results

Search Result, Study Characteristics, and Quality Assessment

Our search identified 3688 publications. After excluding 775 duplicates and 2884 irrelevant studies following abstract screening, 29 full-text articles were retrieved for further assessment. Of these, 16 were excluded for reasons listed in Supplementary Figure S1, leaving 13 studies eligible for inclusion in the systematic review and meta-analysis.\textsuperscript{7,9,11,28,36} We contacted the authors of 6 studies with insufficient data for additional information.\textsuperscript{9,11,31,33,36}

The included 13 studies had a total of 273 patients who underwent 279 TTs. Of these, we excluded 7 patients (8 TTs) who were on a combination including etanercept, apremilast, secukinumab, or ocrelizumab—biologics/SMDS not FDA approved for IBD. A total of 266 patients who underwent 271 TTs of 7 different combination therapies were included in the final systematic review and meta-analysis. There were 188 Crohn’s disease (70.7\%), 75 ulcerative colitis (28.2\%), and 3 IBD-U (1.1\%) patients. Only one of the included studies was a RCT—others were observational studies. Most were single center studies ($n = 8$, 61.5\%), carried out in the United States ($n = 9$, 69.2\%), and published in 2020 ($n = 10$, 76.9\%). The median age of patients in the included studies ranged from 16.9 to 49 years. Fifty-five percent of the patients were female, the median number of prior biologic use across studies ranged from 0 to 4, and the median duration of follow-up ranged from 16 to 68 weeks (Tables 1 and 2). Most patients were started on dual therapy because of active luminal disease. There was significant variation in how clinical and endoscopic effectiveness was assessed across all studies (Table 2). Discontinuation of combination therapy was reported in 72 of 214 TTs (33.6\%).

Eight studies reported outcomes on DBT only,\textsuperscript{7,9,11,28,29,33,35} 3 studies reported outcomes on both DBT and SBT,\textsuperscript{10,32,36} and 2 studies reported outcomes in SBT only.\textsuperscript{30,31} There were 4 DBTs: vedolizumab + ustekinumab (VDZ-UST), vedolizumab + anti-tumor necrosis factor (VDZ-aTNF), ustekinumab + anti-TNF (UST-aTNF) and natalizumab + anti-TNF (NAT-aTNF), and 3 SBTs: tofacitinib + ustekinumab (Tofa-UST), tofacitinib + vedolizumab (Tofa-VDZ), and tofacitinib + anti-TNF (Tofa-aTNF). The most common DBT and SBT were VDZ-aTNF in 56 TTs across 8 studies,\textsuperscript{9,11,28,29,34,36} and Tofa-VDZ in 57 TTs across 5 studies, respectively (Supplementary Table S2).\textsuperscript{10,30,32,36}

Safety

AEs were reported for all 7 combination therapies (Figure 1). Fifteen out of 56 patients on VDZ-aTNF developed AEs (pooled AE rate, ES, 24.1\%; 95\% confidence interval [CI], 11.8–38.4; 8 studies; $F$ 0\%) while AEs were reported in 10 of 57 patients on Tofa-VDZ (ES, 18.3\%; 95\% CI, 3.0–40.0; 5 studies; $F$ 62\%). Among the 49 patients on VDZ-UST, 15 patients developed any AE (ES, 22.8\%; 95\% CI, 5.7–44.5; 7 studies; $F$ 27\%), while 2 out of 16 patients on Tofa-aTNF developed AEs (ES, 6.7\%; 95\% CI, 0.0–32.9; 2 studies; $F$ 0\%). The pooled rates of AEs in other combination therapies are shown in Figure 1.

SAEs were reported by all 13 studies (Figure 2). The pooled rate of SAEs in 56 patients on VDZ-aTNF was 9.6\% (95\% CI, 1.5–21.4; 8 studies; $F$ 0\%) and the rate in 57 patients on Tofa-VDZ was 1.0\% (95\% CI, 0.0–7.6; 5 studies; $F$ 0\%). Among 49 patients on VDZ-UST, the pooled SAE rate was 12.3\% (95\% CI, 2.0–26.8; 7 studies; $F$ 0\%), while pooled SAE rate was 0\% in patients on UST-aTNF, Tofa-UST, Tofa-aTNF, and NAT-aTNF (Figure 2). Table 3 shows a pooled list of all AEs reported for each combination.

Across all combination therapies, the most common SAEs reported were infections, constituting about 75\% (15 of 20) of all SAEs. We therefore separately assessed the rate of infectious SAEs (Supplementary Figure S2) and reported the types of infectious SAEs with various combinations (Supplementary Table S4). The pooled rate of infections SAEs in 56 patients on VDZ-aTNF was 3.6\% (95\% CI, 0.0–13.2; 8 studies; $F$ 0\%) with most infections reported being soft tissue infections ($n = 5$, 55.5\%). Two infectious SAEs (\textit{Clostridiodies difficile} infection and septic arthritis) were reported in 57 patients on Tofa-VDZ with a pooled rate of 1.0\% (95\% CI, 0.0–7.6; 5 studies; $F$ 0\%). A pooled infectious SAE rate of 7.7\% (95\% CI, 0.2–20.9; 7 studies; $F$ 0\%) was reported among the 49 patients on VDZ-UST. Similar to the overall SAE rates, the pooled infections SAE rate was 0\% in patients on UST-aTNF, Tofa-UST, Tofa-aTNF, and NAT-aTNF. The pooled rates of gastrointestinal infections in all combination therapies are shown in Supplementary Figure S3. None of the studies assessing SBT reported a case of herpes zoster (HZ) reactivation. One study reported a recurrent basal cell skin cancer in a patient on VDZ-UST.\textsuperscript{11} The patient was reported to have recurrent history of this cancer prior to initiation of DBT.

Effectiveness

Clinical response was assessed in all 13 studies and clinical remission was reported in all but 1 study.\textsuperscript{7} The pooled clinical response (Supplementary Figure S4) and remission (Figure 3) rates among patients on VDZ-aTNF were 77.9\% (95\% CI, 51.3–97.2; 8 studies; 53 TTs; $F$ 66\%) and 55.1\% (95\% CI, 19.6–88.5; 8 studies; 53 TTs; $F$ 81\%), respectively. Among patients on Tofa-VDZ the pooled clinical response and remission rates were 59.9\% (95\% CI,
| Study type | Country (single/multicenter) | IBD type, \(n (N = 266)^a\) | No. of previous biologies, median (IQR/range) | No. of therapeutic trials, \(n (N = 271)^a\) | Combinatorial treatments | Median duration of follow-up (weeks) | No. of therapeutic trials discontinued DT, \(n/N\) (%) |
|------------|-----------------------------|-----------------------------|--------------------------------------|--------------------------------------|-----------------------------|--------------------------------------|--------------------------------------|
| Sands et al | Randomized controlled trial United States (multicenter) | CD (52) | 0 | 52 | NAT + aTNF | m 32 | 5/52 (9.6%) |
| Buer et al | Prospective cohort Norway (multicenter) | CD (4) UC (6) | NA (R 1–3) | 10 | VDZ + aTNF | 68 | 2/10 (20.0%) |
| Mao et al | Case series United States (single) | CD (3) | 3 (IQR 2–5) | 3 | VDZ + aTNF | NA | 0/3 (0%) |
| Dolinger et al | Retrospective cohort United States (single) | CD (7) UC (8) IBD-U (1) | 3 (IQR 1–2.5) | 16 | VDZ + UST Tofa + UST Tofa + VDZ | 26 | 3/16 (18.8%) |
| Fumery et al | Case series France (single) | CD (4) UC (1) | 2 (IQR 0–4) | 5 | UST + aTNF VDZ + aTNF | 24 | NA |
| Glassner et al | Retrospective cohort United States (single) | CD (30) UC (18) IBD-U (1) | 2 (IQR 1–2) | 52 | VDZ + aTNF VDZ + UST UST + aTNF Tofa + aTNF Tofa + VDZ | 16 | NA |
| Kwapisz et al | Retrospective cohort United States (single) | CD (14) UC (1) | 4 (R 1–7) | 15 | VDZ + aTNF UST + aTNF | 24 | 1/15 (6.7%) |
| Olbjorn et al | Retrospective cohort Norway (single) | CD (9) UC (4) | 1 (R 1–2) | 13 | VDZ + aTNF UST + aTNF | NA | 12/13 (92.3%) |
| Privitera et al | Retrospective cohort Italy (multicenter) | CD (10) UC (3) | 2.5 (IQR 2–3) | 13 | VDZ + aTNF UST + aTNF VDZ + UST | 28 | 4/13 (30.8%) |
| Yang et al | Retrospective cohort United States/Canada (multicenter) | CD (22) | 4 (R 2–5) | 24 | VDZ + aTNF UST + aTNF VDZ + UST | 39 | 15/24 (62.5%) |
| Alayo et al | Retrospective cohort United States (multicenter) | CD (10) UC (2.5) | 2 (IQR 1–3) | 35 | Tofa + aTNF Tofa + UST Tofa + VDZ | 16 | 20/35 (57.1%) |
| Lee et al | Retrospective cohort United States (single) | CD (19) | 4 (IQR 3–4) | 19 | Tofa + aTNF Tofa + UST Tofa + VDZ | 42.3 | 5/19 (26.3%) |
| Llano et al | Retrospective cohort United States (single) | CD (3) UC (10) IBD-U (1) | 2 (R 1–4) | 14 | VDZ + aTNF UST + aTNF UST + VDZ | 31 | 5/14 (35.7%) |

Abbreviations: APR, apremilast; aTNF, anti-tumor necrosis factor; CD, Crohn's disease; DT, dual therapy; ETA, etanercept; IBD, inflammatory bowel disease; IBD-U, inflammatory bowel disease unclassified; IQR, interquartile range; m, mean; NA, not available; NAT, natalizumab; OCR, ocrelizumab; R, range; SKM, secukinumab; Tofa, tofacitinib; UC, ulcerative colitis; UST, ustekinumab; VDZ, vedolizumab. Patients who were on biologics/small molecule drugs not FDA approved for IBD were not included in this table.

Some patients underwent multiples therapeutic trials.

Study was done in pediatric population.
| Study                     | Male (%) | Age (in years) | Baseline CRP/FC\(^a\) | Indication for combination therapy | Clinical effectiveness definitions                                                                 | Endoscopy effectiveness definitions               | EIM assessment                                      |
|--------------------------|----------|----------------|------------------------|-----------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------|-----------------------------------------------------|
| Sands et al\(^1\)       | 24 (46)  | m 39.9 (±12.6) | CRP: m 6.5 mg/L (±11.1) | Active luminal disease            | Response: 70-point decrease from baseline in the CDAI score                                        | NR                                                | NR                                                  |
| Buer et al\(^2\)        | 5 (50)   | 4 (R 22–48)    | CRP: 5.45 mg/dL (R 0.6 to 52.4) | Active luminal disease            | Remission: CDAI <150                                                                                 | Remission: HBI ≤4 or pMS ≤1                        | Remission: CD, absence of ulcerations; UC, Mayo <1 |
| Mao et al\(^3\)         | 3 (75)   | NR             | CRP: 37.4 mg/L (27.2 to 41.0) | Active luminal disease; extraluminal disease | NR                                                                                                   | NR                                                | NR                                                  |
| Dolinger et al\(^4\)    | 8 (50%)  | M 15.9 (IQR 13.5–16.9) | CRP: 5.7 mg/L (1.5 to 23) | Active luminal disease            | Remission: CD; wPCDAI ≤12.5; UC/IBD-U; pMS <2                                                        | NR                                                | NR                                                  |
| Fumery et al\(^5\)      | 4 (57.1) | M 49 (IQR 31–53) | NR                      | Active luminal disease; extraluminal disease; paradoxical adverse event | NR                                                                                                   | NR                                                | NR                                                  |
| Glassner et al\(^6\)    | 16 (32)  | m 36.7 (±13.2) | CRP: 5 mg/dL (1.34 to 23.4) | Active luminal disease; extraluminal disease | Remission: HBI < 5, partial Mayo < 3                                                                  | Remission: SES-CD score 0–2, Rutgeerts score 10–11, or Mayo score 0 | NR                                                  |
| Kwapisz et al\(^7\)     | 5 (33.3) | M 36           | NR                      | Active luminal disease            | Response: CD; PRO UC: partial Mayo score                                                             | NR                                                | NR                                                  |
| Olbjorn et al\(^8\)     | 6 (46)   | M 16 (R 11–17.5) | NR                      | Active luminal disease; extraluminal disease; paradoxical adverse event | NR                                                                                                   | NR                                                | Improvement in psoriasis                            |
| Privitera et al\(^9\)   | 7 (44)   | M 38 (R 27–69) | NR                      | Active luminal disease; extraluminal disease            | NR                                                                                                   | NR                                                | NR                                                  |
| Yang et al\(^10\)       | 10 (45)  | M 35 (IQR 31–43) | CRP: 17 mg/L (11.0 to 24.0) | Active luminal disease            | Response: PRO-2 reduction by 8 Remission: PRO-2 <8                                                   | Remission: >50% reduction in SES-CD or explicitly stated in endo report Remission: SES-CD<3 | NR                                                  |
| Alayo et al\(^11\)      | 17 (49)  | M 32 (IQR 26–39) | CRP: 1.35 mg/dL (0.5 to 11.6) | Active luminal disease            | Response: >50% reduction in symptoms assessed based on PGA Remission: 100% reduction in symptoms assessed based on PGA | Response: CD: >50% reduction in SES-CD or ≥50% reduction in MaRIAs UC: ≥1 grade reduction in Mayo Remission: CD: SES-CD of 0–2 or Global MaRIAs score of < 6; UC: Mayo subscore of 0 or 1 | NR                                                  |
Table 2. Continued

| Name       | Age (in years) | FC* | Baseline CRP/ extraluminal disease | Indication for combination therapy | Clinical effectiveness definitions | Endoscopy effectiveness definitions | EIM assessment |
|------------|----------------|-----|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|----------------|
| Lee et al  | M 40 (IQR 30–50) | CRP: 3.7 mg/dL (1.7 to 4.9) | Active luminal disease; extraluminal disease | Active luminal disease; extraluminal disease | Response: ≥50% decrease in SES-CD | Healing: SES-CD = 0 | Median (interquartile range) except otherwise specified. |
| Lin et al  | M 37 (IQR 28–53) | CRP: 8 mg/dL (<5 to 27) | Active luminal disease | Active luminal disease | Remission: normalisation of HBI/Lichtiger | Response: ≤50% decrease in HBI | Median or mean was not reported. |

Abbreviations: CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; EIM, extraintestinal manifestations; FC, fecal calprotectin; HBI, Harvey–Bradshaw index; IQR, interquartile range; m, mean; MaRIA, Magnetic Resonance Index of Activity; NR, not reported; PGA, Physician Global Assessment; pMS, partial Mayo score; PRO, patient-reported outcome; R, range; SES-CD, Simple Endoscopic Score for Crohn Disease; UC, ulcerative colitis; wPCDAI, weighted Pediatric Crohn’s Disease Activity Index.

Discussion

Here, we present a systematic review and meta-analysis pooling data from 13 studies across different biologics and small molecules to assess the safety and effectiveness of DBT and SBT in IBD patients. We demonstrated that, based on current available data, DBT and SBT appear to be safe with a pooled SAEs rates ranging from 0% (for UST-aTNF [95% CI, 0.0–1.6]) to 37.2–80.8; 5 studies; 49 TTs; F 43%) and 47.8% (95% CI, 19.0–77.4; 5 studies; 49 TTs; F 69%), respectively. VDZ-UST had a pooled clinical response and remission rates of 83.9% (95% CI, 66.4–96.8; 7 studies; 38 TTs; F 0%) and 47.0% (95% CI, 14.5–80.7; 7 studies; 38 TTs; F 64%), respectively. The pooled clinical response and remission rates for other combination therapies are shown in Supplementary Figure S4 and Figure 3, respectively. Similar rates were observed when analysis was limited to patients who were on dual therapy primarily due to active luminal disease only (Supplementary Figures S5 and S6) and when GLMM was used (Supplementary Figures S7 and S8).

Nine studies reported endoscopic and/or radiographic outcomes after initiation of combination therapy, with 6 of these studies providing the criteria for endoscopic assessment. We reported the pooled endoscopic/radiologic response/remission rates for all combinations except NAT-aTNF (Supplementary Figures S9 and S10). The pooled endoscopic/radiologic response and remission rates among patients on VDZ-aTNF were 38.2% (95% CI, 19.5–58.4; 5 studies; 35 TTs; F 0%) and 18.0% (95% CI, 1.6–41.8; 5 studies; 35 TTs; F 32%), respectively. The corresponding rates among patients on Tofa-VDZ were 46.2% (95% CI, 20.4–73.0; 4 studies; 31 TTs; F 40%) and 24.6% (95% CI, 6.4–47.6; 4 studies; 31 TTs; F 25%). Pooled endoscopic/radiologic effectiveness rates observed when analysis was limited to patients who were on dual therapy primarily due to active luminal disease and when GLMM was used are shown in Supplementary Figures S11–S14.

Based on the GRADE framework, the certainty in evidence was very low for all outcomes because of the observational nature of the studies, very serious imprecision (due to the small number of events and patients), and very serious inconsistency between the studies. Due to the small number of studies and substantial heterogeneity, we could not assess for publication bias. There is empirical evidence of publication bias favoring positive results when it comes to case reports and case series in general.37

References

Ahmed et al11,28–31,33,36
Llano et al12,32
Lee et al13
Liu et al14
Previous reviews summarizing studies on safety and efficacy of combination biologics and/or small molecules are either narrative reviews, including mostly case reports with small sample size, or had no patients on SBT. A more recent systematic review and meta-analysis by Ahmed et al12

Supplementary Figures S8

Table 2.

Continued

Supplementary Figures S7 and S8.

We reported the pooled endoscopic/ radiologic response/remission rates for all combinations except NAT-aTNF (Supplementary Figures S9 and S10). The pooled endoscopic/radiologic response and remission rates among patients on VDZ-aTNF were 38.2% (95% CI, 19.5–58.4; 5 studies; 35 TTs; F 0%) and 18.0% (95% CI, 1.6–41.8; 5 studies; 35 TTs; F 32%), respectively. The corresponding rates among patients on Tofa-VDZ were 46.2% (95% CI, 20.4–73.0; 4 studies; 31 TTs; F 40%) and 24.6% (95% CI, 6.4–47.6; 4 studies; 31 TTs; F 25%). Pooled endoscopic/radiologic effectiveness rates observed when analysis was limited to patients who were on dual therapy primarily due to active luminal disease and when GLMM was used are shown in Supplementary Figures S11–S14.

Based on the GRADE framework, the certainty in evidence was very low for all outcomes because of the observational nature of the studies, very serious imprecision (due to the small number of events and patients), and very serious inconsistency between the studies. Due to the small number of studies and substantial heterogeneity, we could not assess for publication bias. There is empirical evidence of publication bias favoring positive results when it comes to case reports and case series in general.37

Discussion

Here, we present a systematic review and meta-analysis pooling data from 13 studies across different biologics and small molecules to assess the safety and effectiveness of DBT and SBT in IBD patients. We demonstrated that, based on current available data, DBT and SBT appear to be safe with a pooled SAEs rates ranging from 0% (for UST-aTNF [95% CI, 0.0–11.1], Tofa-UST [95% CI, 0.0–8.0], Tofa-aTNF [95% CI, 0.0–17.5], and NAT-aTNF [95% CI, 0.0–3.3]) to 12.3% (VDZ-UST [95% CI, 2.0–26.8]). None of the combination therapies assessed in this review revealed any new safety signal. We also observed that DBT and SBT were effective for refractory IBD with pooled clinical remission rates ranging from 40.4% (for Tofa-UST [95% CI, 1.2–88.0]) to 80.0% (UST-aTNF [95% CI, 48.3–99.7]) and endoscopic/radiologic remission rates ranging from 18.0% (for VDZ-aTNF [95% CI, 1.6–41.8]) to 37.4% (Tofa-UST [95% CI, 9.5–69.4]).

Previous reviews summarizing studies on safety and efficacy of combination biologics and/or small molecules are either narrative reviews, including mostly case reports with small sample size, or had no patients on SBT. A more recent systematic review and meta-analysis by Ahmed et al12
reported a single pooled safety and effectiveness estimate for 279 patients on 9 different dual biologics and/or small molecules therapies without providing estimates for each individual combination therapy. These estimates therefore do not account for the significant heterogeneity in combination types. Furthermore, Ahmed et al also included patients on biologics or small molecules which are not currently approved for IBD treatments, therefore diluting the estimates. Therefore, our study is a more comprehensive updated systematic review and meta-analysis with a large pool of patients providing pooled safety and effectiveness estimates for individual DBT or SBT in patients with refractory IBD.

The increasing prevalence of IBD is associated with major healthcare and economic burden, and the chronic inflammatory nature of IBD results in long-term complications, frequent hospitalizations, need for multiple surgeries and decreased quality of life. Although the use of biologics and SMDs has significantly improved outcomes in IBD, significant therapeutic gaps still exist. There has been an increasing interest in exploring the therapeutic potential of combining

| Study                  | Events Total | Any Adverse Event | %   | 95%-CI W(random) |
|------------------------|--------------|-------------------|-----|------------------|
| **Treatment = Vedolizumab + Ustekinumab** |
| Mao, 2018              | 1            | 1                 | 100.0 | [2.5; 100.0] | 8.2%      |
| Dolinger, 2020         | 0            | 4                 | 0.0   | [0.0; 60.2]    | 14.1%     |
| Glassner, 2020         | 10           | 25                | 40.0  | [21.1; 61.3]   | 20.1%     |
| Kwapisz, 2020          | 2            | 5                 | 40.0  | [5.3; 85.3]    | 15.1%     |
| Privitera, 2020        | 0            | 3                 | 0.0   | [0.0; 70.8]    | 12.8%     |
| Yang, 2020             | 1            | 8                 | 12.5  | [0.3; 52.7]    | 17.0%     |
| Liano, 2021            | 1            | 3                 | 33.3  | [0.8; 90.6]    | 12.8%     |
| Random effects model   | 15           | 49                | 22.8  | [5.7; 44.5]    | 100.0%    |
| Heterogeneity: $I^2 = 27%$, $r^2 = 0.0151$, $p = 0.22$ |
| **Treatment = Vedolizumab + anti-TNF** |
| Buer, 2018             | 2            | 10                | 20.0  | [2.5; 55.6]    | 14.3%     |
| Mao, 2018              | 1            | 2                 | 50.0  | [1.3; 98.7]    | 8.8%      |
| Glassner, 2020         | 4            | 7                 | 57.1  | [18.4; 90.1]   | 13.2%     |
| Kwapisz, 2020          | 3            | 8                 | 37.5  | [8.6; 75.5]    | 13.6%     |
| Ottrøm, 2020           | 2            | 8                 | 25.0  | [3.2; 65.1]    | 13.6%     |
| Privitera, 2020        | 1            | 6                 | 16.7  | [0.4; 64.1]    | 12.7%     |
| Yang, 2020             | 2            | 13                | 15.4  | [1.9; 45.4]    | 14.9%     |
| Liano, 2021            | 2            | 0                 | 0.0   | [0.0; 84.2]    | 8.8%      |
| Random effects model   | 15           | 56                | 24.1  | [11.8; 38.4]   | 100.0%    |
| Heterogeneity: $I^2 = 0%$, $r^2 = 0.0$, $p = 0.62$ |
| **Treatment = Ustekinumab + anti-TNF** |
| Fumery, 2020           | 0            | 5                 | 0.0   | [0.0; 52.2]    | 22.2%     |
| Kwapisz, 2020          | 1            | 2                 | 50.0  | [1.3; 98.7]    | 16.1%     |
| Ottrøm, 2020           | 1            | 5                 | 20.0  | [0.5; 71.6]    | 22.2%     |
| Privitera, 2020        | 1            | 4                 | 25.0  | [0.6; 80.6]    | 20.7%     |
| Yang, 2020             | 2            | 3                 | 0.0   | [0.0; 70.8]    | 18.8%     |
| Random effects model   | 3            | 19                | 19.6  | [0.0; 33.4]    | 100.0%    |
| Heterogeneity: $I^2 = 0%$, $r^2 = 0.0$, $p = 0.52$ |
| **Treatment = Tofacitinib + Ustekinumab** |
| Dolinger, 2020         | 0            | 3                 | 0.0   | [0.0; 70.8]    | 21.8%     |
| Glassner, 2020         | 1            | 3                 | 33.3  | [0.8; 90.6]    | 21.8%     |
| Alayo, 2021            | 0            | 5                 | 0.0   | [0.0; 52.2]    | 25.7%     |
| Lee, 2021              | 5            | 11                | 45.5  | [16.7; 76.6]   | 30.8%     |
| Random effects model   | 6            | 22                | 17.0  | [0.0; 49.9]    | 100.0%    |
| Heterogeneity: $I^2 = 46%$, $r^2 = 0.0399$, $p = 0.13$ |
| **Treatment = Tofacitinib + Vedolizumab** |
| Dolinger, 2020         | 1            | 9                 | 11.1  | [0.3; 48.2]    | 19.7%     |
| Glassner, 2020         | 1            | 8                 | 12.5  | [0.3; 52.7]    | 19.2%     |
| Alayo, 2021            | 1            | 24                | 4.2   | [0.1; 21.1]    | 22.6%     |
| Lee, 2021              | 2            | 7                 | 28.6  | [3.7; 71.0]    | 18.7%     |
| Liano, 2021            | 5            | 9                 | 55.6  | [21.2; 86.3]   | 19.7%     |
| Random effects model   | 10           | 57                | 18.3  | [3.0; 40.0]    | 100.0%    |
| Heterogeneity: $I^2 = 62%$, $r^2 = 0.0367$, $p = 0.03$ |
| **Treatment = Tofacitinib + anti-TNF** |
| Glassner, 2020         | 1            | 9                 | 11.1  | [0.3; 48.2]    | 42.0%     |
| Alayo, 2021            | 1            | 6                 | 16.7  | [0.4; 64.1]    | 38.3%     |
| Lee, 2021              | 0            | 1                 | 0.0   | [0.0; 97.5]    | 19.8%     |
| Random effects model   | 2            | 16                | 6.7   | [0.0; 32.9]    | 100.0%    |
| Heterogeneity: $I^2 = 0%$, $r^2 = 0.0$, $p = 0.95$ |
| **Treatment = Natalizumab + anti-TNF** |
| Sands, 2007            | 48           | 52                | 92.3  | [81.5; 97.9]   | 100.0%    |
| Random effects model   | 48           | 52                | 92.3  | [83.2; 98.3]   | 100.0%    |
| Heterogeneity: not applicable |

Figure 1. Forest plot of pooled adverse events rates for different combination therapies. Abbreviations: CI, confidence interval; TNF, tumor necrosis factor; W, weights.
mechanically different biologics and/or SMDs to further bridge the remaining gap in therapy. However, there are concerns about the safety of this approach.

These safety concerns come largely from experience in using combination biologic therapy in rheumatological diseases, for which more high-quality prospective studies have been performed. A meta-analysis by Boleto et al which included a total of 623 RA patients (410 on DBT and 213 on single biologic) with a median follow-up of 9.5 months, suggested that DBT in RA appeared to increase the risk of SAEs (14.9\% vs 6.0\%). However, the biologics used in these studies, such as abatacept, rituximab, or tocilizumab are not used in IBD, and generally tend to have poorer safety profiles compared to the biologics/SMD reported in our meta-analysis. The safety profile of gut-specific anti-integrin agents such as VDZ also provides some reassurance. In addition, the only RCT published on DBT in IBD, which compared a combination of infliximab (an aTNF) and NAT (anti-integrin agent) to

| Study | Events Total | Serious Adverse Events | % | 95%-CI W(random) |
|-------|--------------|------------------------|---|-----------------|
| Treatment = Vedolizumab + Ustekinumab | Mao, 2018 0 1 | 0.0 [0.0; 97.5] | 3.5% | |
| Dolinger, 2020 0 4 | 0.0 [0.0; 60.2] | 10.0% | |
| Glassner, 2020 5 25 | 20.0 [6.8; 40.7] | 40.9% | |
| Kwapisz, 2020 2 5 | 40.0 [5.3; 85.3] | 12.0% | |
| Privitera, 2020 0 3 | 0.0 [0.0; 70.6] | 7.9% | |
| Yang, 2020 1 1 | 12.5 [3.2; 52.7] | 17.6% | |
| Llano, 2021 1 3 | 33.3 [6.8; 90.6] | 7.9% | |
| Random effects model 9 49 | 12.3 [2.0; 26.8] | 100.0% | |
| Heterogeneity: I^2 = 0\% , t^2 = 0 , p = 0.76 |

| Study | Events Total | Serious Adverse Events | % | 95%-CI W(random) |
|-------|--------------|------------------------|---|-----------------|
| Treatment = Vedolizumab + anti-TNF | Buer, 2018 0 10 | 0.0 [0.0; 30.8] | 17.1% | |
| Mao, 2018 0 2 | 0.0 [0.0; 84.2] | 4.7% | |
| Glassner, 2020 2 7 | 28.6 [3.7; 71.0] | 12.8% | |
| Kwapisz, 2020 2 8 | 25.0 [3.2; 65.1] | 14.3% | |
| Oblaj, 2020 2 8 | 25.0 [3.2; 65.1] | 14.5% | |
| Privitera, 2020 1 6 | 16.7 [4.4; 64.1] | 11.3% | |
| Yang, 2020 1 13 | 7.7 [0.2; 36.0] | 20.9% | |
| Llano, 2021 0 2 | 0.0 [0.0; 84.2] | 4.7% | |
| Random effects model 8 56 | 9.6 [1.5; 21.4] | 100.0% | |
| Heterogeneity: I^2 = 0\% , t^2 = 0 , p = 0.58 |

| Study | Events Total | Serious Adverse Events | % | 95%-CI W(random) |
|-------|--------------|------------------------|---|-----------------|
| Treatment = Ustekinumab + anti-TNF | Fumery, 2020 0 5 | 0.0 [0.0; 52.2] | 25.2% | |
| Kwapisz, 2020 0 2 | 0.0 [0.0; 84.2] | 12.1% | |
| Oblaj, 2020 0 5 | 0.0 [0.0; 52.2] | 25.2% | |
| Privitera, 2020 0 4 | 0.0 [0.0; 60.2] | 21.0% | |
| Yang, 2020 0 3 | 0.0 [0.0; 70.8] | 16.8% | |
| Random effects model 0 19 | 0.0 [0.0; 11.1] | 100.0% | |
| Heterogeneity: I^2 = 0\% , t^2 = 0 , p = 1.00 |

| Study | Events Total | Serious Adverse Events | % | 95%-CI W(random) |
|-------|--------------|------------------------|---|-----------------|
| Treatment = Tofacitinib + Ustekinumab | Dolinger, 2020 0 3 | 0.0 [0.0; 70.8] | 15.7% | |
| Glassner, 2020 0 3 | 0.0 [0.0; 70.8] | 15.7% | |
| Alayo, 2021 0 5 | 0.0 [0.0; 52.2] | 23.6% | |
| Lee, 2021 0 11 | 0.0 [0.0; 28.5] | 44.8% | |
| Random effects model 0 22 | 0.0 [0.0; 8.0] | 100.0% | |
| Heterogeneity: I^2 = 0\% , t^2 = 0 , p = 0.97 |

| Study | Events Total | Serious Adverse Events | % | 95%-CI W(random) |
|-------|--------------|------------------------|---|-----------------|
| Treatment = Tofacitinib + Vedolizumab | Dolinger, 2020 1 9 | 11.1 [0.3; 48.2] | 17.3% | |
| Glassner, 2020 0 8 | 0.0 [0.0; 36.9] | 15.7% | |
| Alayo, 2021 0 24 | 0.0 [0.0; 14.2] | 35.6% | |
| Lee, 2021 0 7 | 0.0 [0.0; 41.0] | 14.1% | |
| Llano, 2021 1 9 | 11.1 [0.3; 48.2] | 17.3% | |
| Random effects model 2 57 | 1.0 [0.0; 7.6] | 100.0% | |
| Heterogeneity: I^2 = 0\% , t^2 = 0 , p = 0.44 |

| Study | Events Total | Serious Adverse Events | % | 95%-CI W(random) |
|-------|--------------|------------------------|---|-----------------|
| Treatment = Tofacitinib + anti-TNF | Glassner, 2020 0 9 | 0.0 [0.0; 33.6] | 52.5% | |
| Alayo, 2021 1 6 | 16.7 [0.4; 64.1] | 37.9% | |
| Lee, 2021 0 1 | 0.0 [0.0; 97.5] | 9.6% | |
| Random effects model 1 16 | 0.0 [0.0; 17.5] | 100.0% | |
| Heterogeneity: I^2 = 0\% , t^2 = 0 , p = 0.45 |

| Study | Events Total | Serious Adverse Events | % | 95%-CI W(random) |
|-------|--------------|------------------------|---|-----------------|
| Treatment = Natalizumab + anti-TNF | Sands, 2007 0 52 | 0.0 [0.0; 6.8] | 100.0% | |
| Random effects model 0 52 | 0.0 [0.0; 3.3] | 100.0% | |
| Heterogeneity: not applicable |

Figure 2. Forest plot of pooled serious adverse events rates for different combination therapies. Abbreviations: CI, confidence interval; TNF, tumor necrosis factor; W, weights.
infliximab alone in refractory CD patients, reported favorable safety outcomes.\textsuperscript{7} Furthermore, individual retrospective case series and previous pooled analyses of these reports have all reported no new safety concerns.\textsuperscript{8} Our study adds to this body of knowledge highlighting that taken together, the preponderance of evidence on DBT and SBT in IBD suggest they are safe.

The safety profiles of the combinations we reported in this meta-analysis are similar to what have been reported for individual biologics or SMDs when used as monotherapy in IBD. In the VARSITY trial, a head-to-head RCT comparing VDZ to adalimumab in moderate-to-severe UC patients, the SAE rates in the VDZ and adalimumab groups were 13.7% and 11.0%, respectively.\textsuperscript{41} Similar SAE rates were reported in a real-world multicenter study comparing the safety profile of VDZ to aTNFs (14% vs 14%).\textsuperscript{42} For UST, Sandborn et al. reported SAE rate of 4.4% (95% CI, 3.5–5.6) and infectious SAE rate of 5.0 (95% CI, 4.0–6.2) in the UST group in a pooled safety analysis of results of phase 2/3 trials of UST in IBD,\textsuperscript{43} and a similar SAEs rate (5.5%) was reported in a pooled analysis of real-world data on UST for Crohn’s disease.\textsuperscript{44} The overall and infectious SAE rates reported in these studies fall within the range of SAE rates we found for DBT in our study (range, overall, 0%–12.3%; infectious, 0%–7.7%). Similarly, the SAE rate for SBT in our meta-analysis (range, 0%–1.0%) is numerically lower than the 5.8% we recently reported in the real-world tofacitinib monotherapy study (TROPIC) as well as the 3.6% and 5.1% reported in the Tofa arm of the pivotal induction trial and maintenance trials, respectively.\textsuperscript{45,46} Unlike the Tofa monotherapy studies that have shown a dose-dependent increase in the risk of HZ infection,\textsuperscript{3} none of the studies assessing SBT reported a case of HZ infection, although this may be due to the relatively short duration of follow-up in these studies or small sample size.

In addition to the favorable safety profile, our results also suggest that combination therapy may be effective. However, this effectiveness should be interpreted with caution given the overall very low certainty with substantial heterogeneity in how and when the response was assessed across all studies, as well as the less stringent definition of response in real-world data compared to RCTs. Despite this, the clinical and endoscopic response and remission rates reported in this meta-analysis are similar to those reported for biologic monotherapies in other real-world studies of UST and VDZ despite a patient population in our analyses that is more refractory to medical therapy overall.\textsuperscript{47,48,49} However, most of the studies in our analysis have a short duration of follow-up, and long-term durability of these clinical and endoscopic outcomes is unclear. Future studies are therefore needed to assess if the clinical and endoscopic improvement rates reported in this meta-analysis persist in RCTs and real-world studies with longer duration of follow-up.

Our systematic review with meta-analysis has several strengths. We utilized a comprehensive search strategy using multiple databases. Secondly, it represents the most comprehensive meta-analysis with a large of patients to assess the safety and effectiveness on individual DBTs and SBTs in refractory IBD patients. Our study also provides important estimates on the AEs and treatment response rates for different combination therapies that can guide shared decision making for clinicians and patients considering DBT or SBT in the setting of refractory IBD and to guide the design of future prospective studies addressing similar questions. Finally, we have also included data from pediatric studies allowing pediatric gastroenterologists to use the information presented here in their decision making.

However, there are a few limitations. Since most of the studies included in this meta-analysis are observational, this

---

**Table 3. List of serious and other adverse events reported by the combination category.**

| Combinations                        | Serious adverse events                                                                 | Other adverse events                                                                 |
|-------------------------------------|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Vedolizumab + ustekinumab           | Abscesses (abdominal wall, pelvic abscesses, perianal), PICC line infection, sepsis, malnutrition, arthralgia, rotavirus infection/high output ostomy, Acinetobacter bacteremia | Clostridioides difficile infection (3), viral enteritis, rotavirus infection, recurrent basal cell skin cancer, sinopulmonary infection (5), viral warts |
| Vedolizumab + anti-TNF              | Peristomal cellulitis, bacterial enteric infection, Clostridioides difficile infection, Salmonella infection, elevated transaminases, eczema (face, scalp, and body), rash, pneumonia | Bacterial enteric infection, perianal abscess, pneumonia, drug-induced lupus, rash, sinopulmonary infection (4), influenza virus infection, hand–foot–mouth disease |
| Ustekinumab + anti-TNF              | —                                                                                      | Perianal abscess, skin infection, otitis externa, tubo-ovarian abscess              |
| Tofacitinib + ustekinumab           | —                                                                                      | Urinary tract infection, sinopulmonary infection, headache, exacerbation of Crohn’s disease, urinary frequency, worsened GERD, rash (2) |
| Tofacitinib + vedolizumab           | Septic arthritis, deep venous thrombosis, Clostridioides difficile infection, paresthesia | Clostridioides difficile infection (2), pneumonia, high LDL, bacterial enteric infection (Escherichia coli), sinopulmonary infection, gluteral abscess, hand injury, basal cell carcinoma, seborrheic dermatitis, rash (2) |
| Tofacitinib + anti-TNF              | Clostridioides difficile infection                                                     | Candida esophagitis, sinopulmonary infection                                       |
| Natalizumab + anti-TNF              | —                                                                                      | Headache (12), fatigue (7), exacerbation of Crohn’s disease (5), dizziness (5), nausea (5), DNA or ANA antibody positive (7), dyspexia (4), abdominal pain (3), arthralgia (3), backpain (3), insomnia (3), pyrexia (3), sinopulmonary infections (8) |

Abbreviations: GERD, gastroesophageal reflux disease; LDL, low-density lipoprotein; PICC, peripherally inserted central catheter; TNF, tumor necrosis factor.
analysis is prone to the bias inherent in the included studies. Indeed, we observed substantial degree of heterogeneity between studies, which is likely due to differences in selection of study population, small sample size, difference in outcome definition, and potential selective reporting of positive outcomes in the original studies. These factors are also responsible for the overall very low certainty in the results presented here and our inability to examine effectiveness by IBD subtype. Furthermore, because of the small sample size within each combination therapy, and the significant heterogeneity between the studies, we were unable to do a head-to-head comparison of the different DBTs or SBTs. Lastly, most of the included studies have a short duration of follow-up and definitions of AEs different from clinical trials. This may partly explain the relatively low rates of AEs, and the high effectiveness rates, however the rates of SAEs are well defined and reliable.

Despite these limitations, in the absence of rigorously designed prospective studies with long-term follow-up data, our results provide the most updated evidence yet on the safety and effectiveness of DBT and SBT across a large group of IBD patients. This information can guide gastroenterologists in making important treatment decisions as they care for patients with refractory luminal or extraintestinal manifestations of IBD. While the absence of new safety signals in this study is reassuring, the overall result of this meta-analysis should be interpreted with caution given the short duration of follow-up and very low certainty of evidence. It is prudent

| Study                     | Events Total | Clinical Remission | %   | 95%-CI W(random) |
|---------------------------|--------------|--------------------|-----|------------------|
| **Treatment = Vedolizumab + Ustekinumab** |              |                    |     |                  |
| Mao, 2018                 | 1            | 1                  | 100.0 [2.5; 100.0] | 8.0% |
| Dolinger, 2020            | 3            | 4                  | 75.0 [19.4; 99.4]  | 14.3% |
| Glassner, 2020            | 7            | 15                 | 46.7 [21.3; 73.4]  | 19.7% |
| Kwapisz, 2020             | 0            | 5                  | 0.0 [0.0; 52.2]    | 15.4% |
| Privitera, 2020           | 0            | 3                  | 0.0 [0.0; 76.8]    | 12.9% |
| Yang, 2020                | 4            | 7                  | 57.1 [18.4; 90.1]  | 16.9% |
| Liño, 2021                | 3            | 3                  | 100.0 [29.2; 100.0] | 12.9% |
| Random effects model      | 18           | 38                 | 47.0 [14.5; 80.7]  | 100.0% |
| Heterogeneity: $r^2 = 64\%$, $t^2 = 0.0816$, $p = 0.01$ |              |                    |     |                  |
| **Treatment = Vedolizumab + anti-TNF** |              |                    |     |                  |
| Buer, 2018                | 10           | 10                 | 100.0 [69.2; 100.0] | 14.6% |
| Mao, 2018                 | 2            | 2                  | 100.0 [15.8; 100.0] | 8.7% |
| Glassner, 2020            | 1            | 5                  | 20.0 [0.5; 71.6]   | 12.2% |
| Kwapisz, 2020             | 0            | 8                  | 0.0 [0.0; 36.9]    | 13.9% |
| Oljbern, 2020             | 4            | 8                  | 50.0 [15.7; 84.3]  | 13.9% |
| Privitera, 2020           | 3            | 6                  | 50.0 [11.8; 88.2]  | 12.9% |
| Yang, 2020                | 4            | 12                 | 33.3 [9.5; 65.1]   | 15.1% |
| Liño, 2021                | 2            | 2                  | 100.0 [15.8; 100.0] | 8.7% |
| Random effects model      | 26           | 53                 | 65.1 [19.6; 88.6]  | 100.0% |
| Heterogeneity: $r^2 = 81\%$, $t^2 = 0.1554$, $p < 0.01$ |              |                    |     |                  |
| **Treatment = Ustekinumab + anti-TNF** |              |                    |     |                  |
| Fumery, 2020              | 4            | 5                  | 80.0 [28.4; 99.5]  | 26.5% |
| Oljbern, 2020             | 5            | 5                  | 100.0 [47.8; 100.0] | 26.5% |
| Privitera, 2020           | 3            | 4                  | 75.0 [19.4; 99.4]  | 24.7% |
| Yang, 2020                | 1            | 3                  | 33.3 [9.8; 60.6]   | 22.2% |
| Random effects model      | 13           | 17                 | 80.4 [48.3; 98.7]  | 100.0% |
| Heterogeneity: $r^2 = 31\%$, $t^2 = 0.0241$, $p = 0.23$ |              |                    |     |                  |
| **Treatment = Tofacitinib + Ustekinumab** |              |                    |     |                  |
| Dolinger, 2020            | 3            | 3                  | 100.0 [29.2; 100.0] | 22.2% |
| Glassner, 2020            | 1            | 3                  | 33.3 [9.8; 60.6]   | 22.2% |
| Alayo, 2021               | 0            | 5                  | 0.0 [0.0; 52.2]    | 26.5% |
| Lee, 2021                 | 3            | 7                  | 42.9 [9.9; 61.6]   | 29.1% |
| Random effects model      | 7            | 18                 | 40.4 [1.2; 88.0]   | 100.0% |
| Heterogeneity: $r^2 = 71\%$, $t^2 = 0.1289$, $p = 0.02$ |              |                    |     |                  |
| **Treatment = Tofacitinib + Vedolizumab** |              |                    |     |                  |
| Dolinger, 2020            | 7            | 9                  | 77.8 [40.0; 97.2]  | 21.2% |
| Glassner, 2020            | 1            | 5                  | 20.0 [0.5; 71.6]   | 18.2% |
| Alayo, 2021               | 7            | 24                 | 29.2 [12.6; 51.1]  | 24.7% |
| Lee, 2021                 | 3            | 3                  | 100.0 [29.2; 100.0] | 15.2% |
| Liño, 2021                | 2            | 8                  | 25.0 [3.2; 65.1]   | 20.7% |
| Random effects model      | 20           | 49                 | 47.8 [19.0; 77.4]  | 100.0% |
| Heterogeneity: $r^2 = 69\%$, $t^2 = 0.0607$, $p = 0.01$ |              |                    |     |                  |
| **Treatment = Tofacitinib + anti-TNF** |              |                    |     |                  |
| Glassner, 2020            | 8            | 9                  | 86.9 [51.8; 99.7]  | 52.5% |
| Alayo, 2021               | 1            | 6                  | 16.7 [0.4; 64.1]   | 47.5% |
| Random effects model      | 9            | 15                 | 55.7 [8.0; 100.0]  | 100.0% |
| Heterogeneity: $r^2 = 87\%$, $t^2 = 0.2142$, $p < 0.01$ |              |                    |     |                  |
| **Test for subgroup differences:** $x^2 = 3.15$, df = 5 (p = 0.68) |              |                    |     |                  |

Figure 3. Forest plot of pooled clinical remission rates for different combination therapies. Abbreviations: CI, confidence interval; TNF, tumor necrosis factor; W, weights.
that clinicians adequately weigh the potential risks and benefits and cost-effectiveness of combining biologics and/or small molecules until more rigorous RCTs data are available to affirm these findings.

**Conclusion**

In conclusion, this systematic review and meta-analysis demonstrated that a combination of 2 biologics or a biologic with a SMD may be safe and potentially effective in patients with refractory IBD. We did not observe any new safety signal across all combinations. However, these findings need to be confirmed in prospective studies. The results of the on-going EXPLORER trial, an open-label study evaluating the combination of VDZ, adalimumab, and methotrexate (ClinicalTrials.gov Identifier: NCT02764762), will likely provide more precise estimates of safety and effectiveness of this triple combination.

**Supplementary Data**

Supplementary data is available at Crohn's and Colitis 360 online.

**Authors’ Contributions**

Quazim A. Alayo, Marc Fenster, Jean-Frederic Colombel, and Parakkal Deepak conceptualized the study and developed the study protocol. Deborah Thomas ran the initial search across databases. Quazim A. Alayo and Marc Fenster screened and reviewed all the published literature, including title, abstract, and full text as well as data extraction. Quazim A. Alayo, Marc Fenster, Kerri L. Glassner, Ernesto Llano, Kindra Clark-Snustad, Anish Patel, Lukasz Kwapisz, Scott D. Lee, Edward V. Loftus Jr., David I. Fudman, and Bincy P. Abraham contributed to the acquisition of the data. Quazim A. Alayo, Osama Altayar, Jean-Frederic Colombel, and Parakkal Deepak analyzed data and drafted the initial manuscript. All authors contributed to the interpretation of study results, reviewed the draft manuscript, and approved the final version of manuscript before its submission.

**Funding**

This research was funded by Washington University Digestive Disease Research Core Center (National Institute of Diabetes and Digestive and Kidney Diseases, grant number P30DK052574). The content is solely the responsibility of the authors and does not necessarily represent the view of the NIH. P.D. is supported by a Junior Faculty Development Award from the American College of Gastroenterology and IBD Plexus of the Crohn’s & Colitis Foundation. M.A.C. is supported by DK109384, a Crohn’s and Colitis Foundation Daniel H Present Senior Research Award (Ref. 370763) and philanthropic support from the Givin’ it all for Guts Foundation (https://givinitallforguts.org) and the Lawrence C. Pakula MD IBD Research Innovation and Education Fund.

**Conflicts of Interest**

Dr. Kindra Clark-Snustad reports personal fees from BMS, personal fees from Pfizer, outside the submitted work. Dr. Anish Patel reports personal fees from JANSSEN, personal fees from TAKEDA, personal fees from AbbVie, outside the submitted work. Dr. Andres J. Yarur reports personal fees from Takeda, personal fees from Prometheus Biosciences, personal fees from Arena Pharmaceutical, personal fees from Bristol Myers Squibb, during the conduct of the study. Dr. Benjamin L. Cohen reports personal fees from AbbVie, personal fees and nonfinancial support from Pfizer, personal fees from Bristol Myers Squibb, personal fees from Janssen, personal fees from Target RWE, personal fees from Sublimity Therapeutics, outside the submitted work. Dr. Matthew A. Ciorba reports grants and personal fees from Pfizer, grants and personal fees from Takeda, outside the submitted work. Dr. Scott D. Lee reports grants and personal fees from AbbVie, grants and personal fees from UCB, grants and personal fees from JANSSEN, grants and personal fees from TAKEDA, grants from BMS, grants from ABGENOMICS, grants and personal fees from ELI LILLY, grants from ARENA, outside the submitted work. Dr. Edward V. Loftus, Jr. reports grants and personal fees from AbbVie, personal fees from Allergan, grants and personal fees from Agen, personal fees from Arena, personal fees from Boehringer Ingelheim, grants and personal fees from Bristol-Myers Squibb, personal fees from Calibr, grants and personal fees from Celgene, personal fees from Celltrion Healthcare, personal fees from Eli Lilly, grants and personal fees from Genentech, grants and personal fees from Gilead, personal fees from Iterative Scopes, grants and personal fees from Janssen, personal fees from Ono Pharma, grants and personal fees from Pfizer, grants from Receptos, grants from Robarts Clinical Trials, personal fees from Sun Pharma, grants and personal fees from Takeda, grants from Theravance, grants and personal fees from UCB, outside the submitted work. Dr. David I. Fudman reports personal fees from Pfizer, outside the submitted work. Dr. Bincy P. Abraham reports personal fees from AbbVie, personal fees from Ferring, grants and personal fees from Takeda, personal fees from Janssen, personal fees from Pfizer, personal fees from Medtronic, personal fees from Samsung bioepis, personal fees from Bristol-Myers Squibb, outside the submitted work. Dr. Jean-Frederic Colombel reports grants and personal fees from AbbVie, personal fees from Agen, personal fees from Allergan, personal fees from Arena Pharmaceuticals, personal fees from Boehringer Ingelheim, personal fees from Bristol-Myers-Squibb, personal fees from Celgene Corporation, personal fees from Celltrion, personal fees from Eli Lilly, personal fees from Enterome, personal fees from Ferring Pharmaceuticals, personal fees from Genentech, personal fees from Gilead, personal fees from Iterative Scopes, personal fees from Ipsen, personal fees from Immuc, personal fees from Intbio, personal fees from Inotrem, grants and personal fees from Janssen Pharmaceuticals, personal fees from Landos, personal fees from Limmatech, personal fees from Medimmune, personal fees from Merck, personal fees from Novartis, personal fees from OMass, personal fees from Otsuka, personal fees from Pfizer, personal fees from Shire, grants and personal fees from Takeda, personal fees from Tigenix, personal fees from VielaBio, outside the submitted work. Dr. Parakkal Deepak reports personal fees from Janssen, personal fees from Pfizer, personal fees from Prometheus Biosciences, other from Boehringer Ingelheim, personal fees from Arena Pharmaceuticals, grants from Takeda Pharmaceuticals, grants from Arena Pharmaceuticals, grants from Bristol Myers...
Squibb-Celgene, grants from Boehringer Ingelheim, outside the submitted work. All other authors declare no competing interests.

**Data Availability**

All data are publicly available in the respective publication of included studies. We have also included other data we obtained directly from authors of included studies in our result sections as well as in the supplementary data.

**References**

1. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. *Am J Gastroenterol*. 2018;113(4):481–517.
2. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. *Am J Gastroenterol*. 2019;114(3):384–413.
3. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. *Gastroenterology*. 2020;158(5):1450–1461.
4. Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. *J Crohns Colitis*. 2020;14(1):4–22.
5. Hirtén RP, Iacucci M, Shah S, et al. Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders. *Clin Gastroenterol Hepatol*. 2018;16(9):1374–1384.
6. Peyrin-Biroulet L, Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. *Aliment Pharmacol Ther*. 2011;33(8):870–879.
7. Sands BE, Kozarek R, Spanhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximab. *Inflamm Bowel Dis*. 2007;13(1):2–11.
8. Ribaldone DG, Pellicano R, Venero M, et al. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. *Scand J Gastroenterol*. 2019;54(4):407–413.
9. Kwapisz L, Raffals LE, Bruining DH, et al. Combination biologic therapy in inflammatory bowel disease: experience from a tertiary care center. *Clin Gastroenterol Hepatol*. 2021;19(3):616–617.
10. Glassner K, Oglat A, Duran A, et al. The use of combination biological or small molecule therapy in inflammatory bowel disease: a retrospective cohort study. *J Dig Dis*. 2020;21(5):264–271.
11. Yang E, Panaccione N, Whitmire N, et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease. *Aliment Pharmacol Ther*. 2020;51(11):1031–1038.
12. Ahmed W, Galati J, Kumar A, et al. Dual biologic or small molecule therapy for treatment of refractory inflammatory bowel disease: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2022;20(3):e561–e579.
13. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. *J Biomed Inform*. 2019;95:103208.
14. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377–381.
15. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. *Meta-analysis Of Observational Studies in Epidemiology (MOOSE)* group. *JAMA*. 2000;283(15):2008–2012.
16. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535.
1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30.

39. Hoivik ML, Moun B, Solberg IC, et al. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut. 2013;62(3):368–375.

40. Boleto G, Kanagaratnam L, Drame M, et al. Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2019;49(1):35–42.

41. Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–1226.

42. Lukin D, Weiss A, Aniwan S, et al. Comparative safety profile of vedolizumab and tumor necrosis factor–antagonist therapy for inflammatory bowel disease: a multicenter consortium propensity score-matched analysis. J Crohns Colitis. 2018;12:S036.

43. Sandborn WJ, Feagan BG, Danese S, et al. Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2/3 studies. Inflamm Bowel Dis. 2021;27(7):994–1007.

44. Engel T, Yung DE, Ma C, et al. Effectiveness and safety of ustekinumab for Crohn’s disease; systematic review and pooled analysis of real-world evidence. Dig Liver Dis. 2019;51(9):1232–1240.

45. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–1736.

46. Deepak P, Alayo QA, Khatiwada A, et al. Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2021;19(8):1592–1601.

47. Colombel JF. Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention. Inflamm Bowel Dis. 2018;24(10):2173–2182.

48. Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53(9):1048–1064.

49. Faleck D, Shashi P, Meserve J, et al. Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicenter consortium propensity score-matched analysis. J Crohns Colitis. 2018;12:S019.